Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 6/20 | 0.38 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1025369 | 0.79 | ALDH1A1 (0.40) | MAPK1TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL11980460 | 0.79 | BAZ1A (0.37) | MAPK1TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL1090688 | 0.79 | ALDH1A1 (0.51) | MAPK1ALDH1A1CYP3A4MAPTBAZ1A | |
| SCHEMBL7894568 | 0.79 | ATM (0.42) | MAPK1ALDH1A1CYP3A4MAPTVCAM1 | |
| SCHEMBL1994756 | 0.79 | MAPT (0.45) | TSHRALDH1A1CYP3A4MAPTBAZ1A | |
| SCHEMBL27087811 | 0.78 | PARP10 (0.50) | MAPK1TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL1512735 | 0.77 | PBRM1 (0.47) | MAPK1HSD17B10PBRM1CASP1CASP7 | |
| SCHEMBL31591225 | 0.77 | PBRM1 (0.47) | MAPK1HSD17B10PBRM1CASP1CASP7 | |
| SCHEMBL7162505 | 0.76 | TYMS (0.53) | MAPK1ALDH1A1CYP3A4MAPTBAZ1A | |
| SCHEMBL30957320 | 0.76 | PGR (0.42) | MAPK1ALDH1A1CYP3A4MAPTVCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-118251393-A | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | 唯久生物技术(苏州)有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-109956928-B | Pyridine compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| EP-1603887-B1 | HIV REPLICATION INHIBITING INDANE SUBSTITUTED PYRIMIDINES | TIBOTEC PHARM LTD (IE) | 2011-04-20 | — | — | EP | disclosed |
| US-7585870-B2 | HIV replication inhibiting pyrimidines and triazines | TIBOTEC BVBA (BE) | 2009-09-08 | — | — | US | disclosed |
| US-7442705-B2 | HIV replication inhibiting pyrimidines and triazines | TIBOTEC PHARMACEUTICALS LTD (IE) | 2008-10-28 | — | — | US | disclosed |
| US-7442705-B2 | HIV replication inhibiting pyrimidines and triazines | TIBOTEC PHARMACEUTICALS LTD (IE) | 2008-10-28 | — | — | US | disclosed |
| EP-1597238-B1 | HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES | TIBOTEC PHARM LTD (IE) | 2007-05-09 | — | — | EP | disclosed |
| EP-1098891-B1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA GMBH (DE) | 2005-08-10 | — | — | EP | disclosed |
| EP-1098891-A1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2001-05-16 | — | — | EP | disclosed |
| US-6159996-A | Polycyclic thiazolidin-2-ylidene amines, process for their preparation, and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-12-12 | — | — | US | disclosed |
| WO-2000004006-A1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-27 | — | — | WO | disclosed |
| US-4174397-A | TREATMENT OF OBESITY AND LIPID METABOLISM DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-11-13 | — | — | US | disclosed |
| US-4129656-A | Thiazolidine derivatives, salidiuretic compositions and methods of effecting salidiuresis employing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | MAPK1 315/4885TSHR 3751/4885ALDH1A1 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.